Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | HSPB1 | P04792 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29572163 | 1.00 | TDP1 (0.43) | TDP1ATMALDH1A1MAPTLMNA | |
| SCHEMBL2368905 | 1.00 | TDP1 (0.43) | TDP1ATMALDH1A1MAPTLMNA | |
| SCHEMBL2368903 | 1.00 | TDP1 (0.43) | TDP1ATMALDH1A1MAPTLMNA | |
| SCHEMBL23050046 | 1.00 | TDP1 (0.43) | TDP1ATMALDH1A1MAPTLMNA | |
| SCHEMBL2369597 | 1.00 | TDP1 (0.43) | TDP1ATMALDH1A1MAPTLMNA | |
| SCHEMBL23049800 | 1.00 | TDP1 (0.43) | TDP1ATMALDH1A1MAPTLMNA | |
| Hydrochloric Acid SCHEMBL2378632 | 0.85 | TDP1 (0.41) | TDP1ATMALDH1A1MAPTLMNA | |
| SCHEMBL23049785 | 0.84 | MEN1 (0.56) | TDP1ATMALDH1A1MAPTMEN1 | |
| SCHEMBL23049784 | 0.84 | MEN1 (0.56) | TDP1ATMALDH1A1MAPTMEN1 | |
| SCHEMBL20574163 | 0.84 | MEN1 (0.56) | TDP1ATMALDH1A1MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3939981-B1 | FUSED THIAZOLOPYRIMIDINE DERIVATIVES AS MNKS INHIBITORS | LIFEARC (GB) | 2024-04-03 | — | — | EP | disclosed |
| EP-3792264-B1 | PYRROPYRIMIDINE COMPOUNDS AS MNKS INHIBITORS | LIFEARC (GB) | 2024-01-03 | — | — | EP | disclosed |
| CN-108368114-B | Pyrrolopyrimidine compounds as MNK inhibitors | 生命弧度公司 | 2023-10-24 | — | — | CN | disclosed |
| CN-108495855-B | Fused thiazolopyrimidine derivatives as MNK inhibitors | 生命弧度公司 | 2022-05-31 | — | — | CN | disclosed |
| EP-3939981-A1 | FUSED THIAZOLOPYRIMIDINE DERIVATIVES AS MNKS INHIBITORS | LifeArc (GB) | 2022-01-19 | — | — | EP | disclosed |
| US-11136338-B2 | Fused thiazolopyrimidine derivatives as MNKs inhibitors | LIFEARC (GB) | 2021-10-05 | — | — | US | disclosed |
| US-11136338-B2 | Fused thiazolopyrimidine derivatives as MNKs inhibitors | LIFEARC (GB) | 2021-10-05 | — | — | US | disclosed |
| EP-3377501-B1 | FUSED THIAZOLOPYRIMIDINE DERIVATIVES AS MNKS INHIBITORS | LIFEARC (GB) | 2021-08-18 | — | — | EP | disclosed |
| EP-3792264-A1 | PYRROPYRIMIDINE COMPOUNDS AS MNKS INHIBITORS | LifeArc (GB) | 2021-03-17 | — | — | EP | disclosed |
| EP-3377494-B1 | PYRROPYRIMIDINE COMPOUNDS AS MNKS INHIBITORS | LIFEARC (GB) | 2021-03-03 | — | — | EP | disclosed |
| US-10604524-B2 | Pyrropyrimidine compounds as MNKs inhibitors | LIFE ARC (GB) | 2020-03-31 | — | — | US | disclosed |
| US-20180346469-A1 | Pyrropyrimidine Compounds As MNKS Inhibitors | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2018-12-06 | — | — | US | disclosed |
| US-20180346483-A1 | Fused Thiazolopyrimidine Derivatives As MNKS Inhibitors | LIFEARC (GB) | 2018-12-06 | — | — | US | disclosed |
| EP-2539345-B1 | 4-[CYCLOALKYLOXY(HETERO)ARYLAMINO]-THIENO[2,3-D]PYRIMIDINES HAVING MNK1/ MNK2 INHIBITING ACTIVITY FOR PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INT (DE) | 2015-07-22 | — | — | EP | disclosed |
| US-8754079-B2 | Cycloalkyl containing thienopyrimidines for pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-06-17 | — | — | US | disclosed |
| US-8754079-B2 | Cycloalkyl containing thienopyrimidines for pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-06-17 | — | — | US | disclosed |
| EP-2539345-A1 | 4 - [CYCLOALKYLOXY (HETERO) ARYLAMINO]THIENO [2, 3 - D]PYRIMIDINES HAVING MNKL/ MNK2 INHIBITING ACTIVITY FOR PHARMACEUTICAL COMPOSITIONS | Boehringer Ingelheim International GmbH (DE) | 2013-01-02 | — | — | EP | disclosed |
| US-20110217311-A1 | CYCLOALKYL CONTAINING THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-09-08 | — | — | US | disclosed |
| US-20110217311-A1 | CYCLOALKYL CONTAINING THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-09-08 | — | — | US | disclosed |
| WO-2011104334-A1 | 4 - [CYCLOALKYLOXY (HETERO) ARYLAMINO] THIENO [2, 3 - D] PYRIMIDINES HAVING MNKL/ MNK2 INHIBITING ACTIVITY FOR PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180346483-A1 | Fused Thiazolopyrimidine Derivatives As MNKS Inhibitors | MAPT, TTBK1, TTBK2 | TDP1 622/4885ATM 232/4885ALDH1A1 3501/4885 |
| US-20180346469-A1 | Pyrropyrimidine Compounds As MNKS Inhibitors | NR0B1, NR4A1, NR2E1 | TDP1 3238/4885ATM 2758/4885ALDH1A1 4356/4885 |
| US-10604524-B2 | Pyrropyrimidine compounds as MNKs inhibitors | NR0B1, NR2E1, HRH4 | TDP1 2786/4885ATM 2438/4885ALDH1A1 4251/4885 |
| US-20110217311-A1 | CYCLOALKYL CONTAINING THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | DTYMK, CMPK1, UCK2 | TDP1 508/4885ATM 408/4885ALDH1A1 4123/4885 |
| US-11136338-B2 | Fused thiazolopyrimidine derivatives as MNKs inhibitors | MAPT, TTBK1, TTBK2 | TDP1 611/4885ATM 226/4885ALDH1A1 3442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.